New York Academy of Sciences:Subscription Services Department, 2 East 63rd Street:New York, NY 10021:(800)843-6927, (212)838-0230, EMAIL: [email protected], INTERNET: http://www.nyas.org, Fax: (212)888-2894
Doi
Abstract
Apoptosis may be viewed as a triphasic process. During the premitochondrial
initiation phase, very different pro-apoptotic signal transduction
or damage pathways can be activated. These pathways then converge on
the mitochondrion, where they cause the permeabilization of the inner and/or
outer membranes with consequent release of soluble intermembrane proteins
into the cytosol. The process of mitochondrial membrane permeabilization
would constitute the decision/effector phase of the apoptotic process. During
the post-mitochondrial degradation phase downstream caspases and nucleases
are activated and the cell acquires an apoptotic morphology. Recently, a number
of different second messengers (calcium, ceramide derivatives, nitric oxide,
reactive oxygen species) and pro-apoptotic proteins (Bax, Bak, Bid, and
caspases) have been found to directly compromise the barrier function of mitochondrial
membranes, when added to isolated mitochondria. The effects of
several among these agents are mediated at least in part via the permeability
transition pore complex (PTPC), a composite channel in which members of the
Bcl-2 family interact with sessile transmembrane proteins such as the adenine
nucleotide translocator. These findings suggest that the PTPC may constitute
a pharmacological target for chemotherapy and cytoprotection